BOULDER, CO, Enveda, a biotechnology company using AI to translate nature into new medicines, announced today an oversubscribed $130 million Series C funding round.
The round was led by Kinnevik and FPV with participation from new and existing investors Baillie Gifford, Premji Invest, Lingotto Innovation, Lux Capital, Dimension Capital, True Ventures, Cresset Partners, The Nature Conservancy, and Henry R. Kravis. This brings the company's total funding to $360 million.
Enveda is a biotechnology company that is learning from life's chemistry to create better medicines faster. Enveda uses AI-powered tools to identify and characterize a wide range of molecules produced by living organisms-the vast majority of which have never been explored by science-creating a database of chemical biodiversity: the library of life. By growing, organizing, translating, and searching this unique library, Enveda learns from life's evolved solutions to address today's pressing medical needs.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.